口服AKST4290治疗新诊断新生血管性年龄相关性黄斑变性的安全性和治疗效果
这项前瞻性、多中心、开放标签的2a期试点临床研究纳入30例新诊断的新生血管性年龄相关性黄斑变性患者,口服AKST4290(400 mg)每日两次、持续6周。主要终点为最佳矫正视力(BCVA)从基线至治疗结束的平均变化,结果为+7.0个字母(95%CI 2.2-11.7);24例(82.8%)患者BCVA稳定或改善,6例(20.7%)提升≥15个字母。所有不良事件均为轻中度,未发生严重或重度不良事件,作者认为该治疗值得在随机安慰剂对照试验中进一步研究。
要点
- 30例新诊断新生血管性AMD患者口服AKST4290 400 mg每日两次,持续6周。
- BCVA平均提升+7.0个字母(95%CI 2.2-11.7),24例(82.8%)稳定或改善,6例(20.7%)提升≥15个字母。
- 所有不良事件均为轻中度,未发生严重或重度不良事件,未发现安全性问题。
核心结论
- 在这项为期6周的研究中,AKST4290治疗与新诊断新生血管性年龄相关性黄斑变性患者的BCVA评分改善相关。
- 所有不良事件均为轻中度,未发现安全性问题。
- 作者认为AKST4290治疗新生血管性年龄相关性黄斑变性值得在随机安慰剂对照试验中进一步研究。
研究设计与样本
- 前瞻性、多中心、开放标签的2a期试点临床研究,纳入30例新诊断的新生血管性年龄相关性黄斑变性患者。
- 患者自行口服AKST4290(400 mg)每日两次,持续6周,每周随访进行安全性检查、BCVA测量和探索性形态学评估。
- 主要终点为BCVA从基线至治疗结束的平均变化,次要终点为安全性,探索性终点为黄斑形态的潜在变化。
主要发现
- BCVA平均改善+7.0个字母(95%CI 2.2-11.7)。
- 24例(82.8%)患者BCVA稳定或改善,其中6例(20.7%)提升≥15个字母。
- 没有患者发生重度或严重不良事件,所有不良事件均为轻中度。
关键数值与推荐
- AKST4290口服剂量为400 mg,每日两次,持续6周。
- BCVA平均变化为+7.0个字母(95%CI 2.2-11.7)。
- 24例(82.8%)患者BCVA稳定或改善,6例(20.7%)提升≥15个字母。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出AKST4290治疗新生血管性年龄相关性黄斑变性值得在随机安慰剂对照试验中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and therapeutic effects of orally administered AKST4290 (formerly BI 144807 and ALK4290) in treatment-naive patients with neovascular age-related macular degeneration. METHODS: In this prospective, multicenter, open-label Phase 2a pilot clinical study, 30 patients with newly diagnosed neovascular age-related macular degeneration self-administered AKST4290 (400 mg) orally twice daily for 6 weeks. Patients were examined weekly for safety, to measure best-corrected visual acuity (BCVA), and to perform exploratory morphologic assessments. The primary endpoint was the mean change in BCVA from baseline to end of treatment, and the secondary endpoint was safety. Exploratory endpoints investigated potential changes in macular morphology. RESULTS: Mean BCVA improved by +7.0 letters (95% CI, 2.2-11.7); 24 patients (82.8%) had stable or improved BCVA, with 6 (20.7%) gaining ≥15 letters. No patients experienced severe or serious adverse events. CONCLUSION: In this 6-week study, AKST4290 treatment was associated with improved BCVA scores in patients with treatment-naive neovascular age-related macular degeneration. All adverse events were mild or moderate in severity and no safety issues were identified. Treatment of neovascular age-related macular degeneration with AKST4290 warrants further investigation in randomized, placebo-controlled trials.
引用
- Stewart MW, Garg S, Newman EM, et al. SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022. PMID: 35537111. doi:10.1097/IAE.0000000000003446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。